Alkermes Showcases Psychiatry Data at Spring 2024 Conferences
Alkermes plc, a leading global biopharmaceutical company, recently announced the presentation of new research findings related to its psychiatric products, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), at four major scientific conferences this spring. The conferences coincide with Mental Health Awareness Month in May, a time dedicated to increasing understanding of mental health conditions, supporting those affected, and acknowledging the contributions of healthcare professionals.
The conferences where Alkermes will present their findings include:
1. American Psychiatric Association (APA) Annual Meeting, May 4-8, New York City
2. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, May 5-8, Atlanta
3. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 28-31, Miami Beach
4. Psych Congress Elevate, May 30–June 2, Las Vegas
Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes, emphasized the importance of these events for sharing knowledge and advancing patient care. He highlighted Alkermes' commitment to enhancing the body of evidence for their psychiatric medicines and improving the understanding of their real-world impact.
Key highlights of the presentations include the results from a long-term safety study on LYBALVI and data from a study on healthcare resource utilization involving patients treated with ARISTADA. The long-term study on LYBALVI is an international, multicenter, phase 3, open-label extension study that evaluated the drug's safety, tolerability, and effectiveness over up to four years of treatment. The research on ARISTADA focuses on treatment patterns and healthcare resource use among schizophrenia patients before and after starting ARISTADA using the ARISTADA INITIO® regimen.
The detailed list of presentations at each conference includes:
APA Annual Meeting:
- Poster 5749: Long-term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study
ISPOR Annual Meeting:
- Poster RWD194: Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder
- Poster RWD103: Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
ASCP Annual Meeting:
- Poster T47: Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia
- Poster T49: Long-Term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study
- Poster T52: Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
Psych Congress Elevate:
- Poster #59: Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
- Poster #30: Long-term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study
- Poster #60: Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder
About LYBALVI® (olanzapine and samidorphan):
LYBALVI® is an oral atypical antipsychotic medication approved in the United States for treating adults with schizophrenia and bipolar I disorder. It is a combination of olanzapine, an atypical antipsychotic, and samidorphan, an opioid antagonist, available in fixed dosage strengths.
About ARISTADA® (aripiprazole lauroxil):
ARISTADA is an injectable atypical antipsychotic approved for treating schizophrenia in adults. It is available in multiple dose strengths and dosing intervals. ARISTADA INITIO® is a related product used in combination with oral aripiprazole for initiating ARISTADA treatment.
This presentation of research data underscores Alkermes' dedication to advancing treatments for severe psychiatric conditions and improving the quality of life for patients.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
